Logo image of TMCI

TREACE MEDICAL CONCEPTS INC (TMCI) Stock Fundamental Analysis

NASDAQ:TMCI - Nasdaq - US89455T1097 - Common Stock - Currency: USD

9.37  -0.29 (-3%)

After market: 9.55 +0.18 (+1.92%)

Fundamental Rating

3

TMCI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. While TMCI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, TMCI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TMCI has reported negative net income.
In the past year TMCI has reported a negative cash flow from operations.
TMCI had negative earnings in each of the past 5 years.
TMCI had a negative operating cash flow in each of the past 5 years.
TMCI Yearly Net Income VS EBIT VS OCF VS FCFTMCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of TMCI (-28.89%) is comparable to the rest of the industry.
TMCI has a Return On Equity of -58.65%. This is comparable to the rest of the industry: TMCI outperforms 45.21% of its industry peers.
Industry RankSector Rank
ROA -28.89%
ROE -58.65%
ROIC N/A
ROA(3y)-20.43%
ROA(5y)-17.61%
ROE(3y)-42.96%
ROE(5y)-163.9%
ROIC(3y)N/A
ROIC(5y)N/A
TMCI Yearly ROA, ROE, ROICTMCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -100 -200 -300 -400 -500

1.3 Margins

TMCI has a Gross Margin of 80.61%. This is amongst the best in the industry. TMCI outperforms 93.62% of its industry peers.
In the last couple of years the Gross Margin of TMCI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TMCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5YN/A
TMCI Yearly Profit, Operating, Gross MarginsTMCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 20 -20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TMCI has been increased compared to 1 year ago.
The debt/assets ratio for TMCI has been reduced compared to a year ago.
TMCI Yearly Shares OutstandingTMCI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
TMCI Yearly Total Debt VS Total AssetsTMCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.66 indicates that TMCI is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.66, TMCI is in the better half of the industry, outperforming 64.36% of the companies in the same industry.
TMCI has a Debt/Equity ratio of 0.51. This is a neutral value indicating TMCI is somewhat dependend on debt financing.
TMCI has a worse Debt to Equity ratio (0.51) than 62.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z 2.66
ROIC/WACCN/A
WACC9.04%
TMCI Yearly LT Debt VS Equity VS FCFTMCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.12 indicates that TMCI has no problem at all paying its short term obligations.
TMCI has a better Current ratio (4.12) than 70.74% of its industry peers.
A Quick Ratio of 2.98 indicates that TMCI has no problem at all paying its short term obligations.
TMCI has a Quick ratio of 2.98. This is in the better half of the industry: TMCI outperforms 64.89% of its industry peers.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 2.98
TMCI Yearly Current Assets VS Current LiabilitesTMCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for TMCI have decreased strongly by -18.99% in the last year.
TMCI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.13%.
The Revenue has been growing by 48.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-18.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y48.28%
Revenue growth 5YN/A
Sales Q2Q%10.62%

3.2 Future

TMCI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.00% yearly.
Based on estimates for the next years, TMCI will show a quite strong growth in Revenue. The Revenue will grow by 14.06% on average per year.
EPS Next Y-16.75%
EPS Next 2Y3.26%
EPS Next 3Y5.77%
EPS Next 5Y11%
Revenue Next Year12.15%
Revenue Next 2Y10.37%
Revenue Next 3Y10.3%
Revenue Next 5Y14.06%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMCI Yearly Revenue VS EstimatesTMCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
TMCI Yearly EPS VS EstimatesTMCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TMCI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMCI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMCI Price Earnings VS Forward Price EarningsTMCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMCI Per share dataTMCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.26%
EPS Next 3Y5.77%

More info and screens

0

5. Dividend

5.1 Amount

TMCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREACE MEDICAL CONCEPTS INC

NASDAQ:TMCI (2/21/2025, 8:00:01 PM)

After market: 9.55 +0.18 (+1.92%)

9.37

-0.29 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners60.6%
Inst Owner Change-4.56%
Ins Owners24.78%
Ins Owner Change8.54%
Market Cap583.75M
Analysts72.31
Price Target10.59 (13.02%)
Short Float %4.96%
Short Ratio6.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.87%
Min EPS beat(2)1.96%
Max EPS beat(2)9.78%
EPS beat(4)3
Avg EPS beat(4)0.98%
Min EPS beat(4)-10.69%
Max EPS beat(4)9.78%
EPS beat(8)6
Avg EPS beat(8)7.74%
EPS beat(12)8
Avg EPS beat(12)-182.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.5%
Min Revenue beat(2)1.36%
Max Revenue beat(2)1.65%
Revenue beat(4)4
Avg Revenue beat(4)1.46%
Min Revenue beat(4)0.73%
Max Revenue beat(4)2.12%
Revenue beat(8)7
Avg Revenue beat(8)2%
Revenue beat(12)11
Avg Revenue beat(12)3.12%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34.41%
PT rev (3m)51.03%
EPS NQ rev (1m)-5.18%
EPS NQ rev (3m)-5.18%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)-0.23%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.88
P/FCF N/A
P/OCF N/A
P/B 5.56
P/tB 6.97
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS3.26
BVpS1.68
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.89%
ROE -58.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.61%
FCFM N/A
ROA(3y)-20.43%
ROA(5y)-17.61%
ROE(3y)-42.96%
ROE(5y)-163.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5YN/A
F-Score2
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 135.37%
Cap/Sales 5.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 2.98
Altman-Z 2.66
F-Score2
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)434.52%
Cap/Depr(5y)309.03%
Cap/Sales(3y)6.49%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
EPS Next Y-16.75%
EPS Next 2Y3.26%
EPS Next 3Y5.77%
EPS Next 5Y11%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y48.28%
Revenue growth 5YN/A
Sales Q2Q%10.62%
Revenue Next Year12.15%
Revenue Next 2Y10.37%
Revenue Next 3Y10.3%
Revenue Next 5Y14.06%
EBIT growth 1Y-29.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.82%
EBIT Next 3Y28.41%
EBIT Next 5Y21.79%
FCF growth 1Y-1.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.66%
OCF growth 3YN/A
OCF growth 5YN/A